News & Events

• Interview with Jim Weston and Stephen Conafay of MTIG
  Published on 2019-10-01
• Microbiome Therapeutics Innovation Group Highlights Member Company Activity at IDWeek 2019
  Published on 2019-10-01
• Vedanta Biosciences Announces $16.6 Million Series C-2 Financing
  Published on 2019-09-23
• LUCA Biologics Launches to Develop Live Biotherapeutics for Women’s Health Starting with Urinary Tract Infection (UTI)
  Published on 2019-08-07
• Seres Therapeutics Reports Second Quarter Financial Results and Provides Progress Update
  Published on 2019-08-06
• Seres Therapeutics Appoints Stephen Berenson to its Board of Directors
  Published on 2019-08-06
• Seres Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference
  Published on 2019-08-01
• Seres Therapeutics to Host Second Quarter 2019 Financial Results and Operational Progress Conference Call and Webcast on August 6, 2019
  Published on 2019-08-01
• Seed Health Joins Microbiome Therapeutics Innovation Group
  Published on 2019-07-16
• Rebiotix Leaders to Discuss Microbiome Product Development Challenges and Regulation at Microbiome Movement – Drug Development Summit 2019
  Published on 2019-07-01
• Vedanta Biosciences Announces First Patient Enrolled in VE416 Phase 1b/2 Food Allergy Clinical Study
  Published on 2019-07-01
• Vedanta Biosciences’ Silvia Caballero, Ph.D., Named as an MIT Technology Review Global Innovator Under 35
  Published on 2019-06-25
• Seres Therapeutics Issues Statement Regarding U.S. Food and Drug Administration Safety Alert Related to Use of Fecal Microbiota Transplantation
  Published on 2019-06-19
• Microbiome Therapeutics Innovation Group Statement on FDA Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse Reactions Due to Transmission of Multi-Drug Resistant Organisms
  Published on 2019-06-17
• Seres Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
  Published on 2019-06-13